APP and Alzheimer disease: The AppG–F mice are more suitable for preclinical studies of β-secretase inhibition given that the Swedish mutation affects the reactivity of APP to β-site amyloid precursor protein cleaving enzyme 1 (BACE1) and most AD patients do not carry Swedish mutations (Watamura et al., 2021b).